Abstracts tagged "Bone density"

Abstract Number: 1007 • 2012 ACR/ARHP Annual Meeting
High Resolution Peripheral Quantitative CT Detects Marked Differences in Metacarpal Head and Shaft and Ultra-Ultra-Distal Radius Bone Volumetric Density and Microstructure in Early Rheumatoid Arthritis
Lynne M. Feehan¹, Helen R. Buie², Linda C. Li¹, Kamran Shojania³, Cheryl Barnabe⁴ and Heather A. McKay⁵, ¹Physical Therapy, Arthritis Research Centre of Canada and University of British Columbia, Vancouver, BC, Canada, ²Mechanical Engineering, University of Calgary, Calgary, AB, Canada, ³Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁴Medicine, Community Health Sciences, University of Calgary, Calgary, AB, Canada, ⁵Family Practice and Orthoepedics, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Despite improvements in clinical management of rheumatoid arthritis (RA), many with early disease are still at high risk for developing periarticular erosions and osteopenia,…
Abstract Number: 2415 • 2012 ACR/ARHP Annual Meeting
Does Interleukin-6 Mediate the Relation Between Estrogen and Bone? an Epidemiologic Approach in the Framingham Osteoporosis Study
Robert R. McLean¹, Xiaochun Zhang², Andrea D. Coviello³, Joao D.T. Fontes⁴, L. Adrienne Cupples⁵, Douglas P. Kiel⁶ and Marian T. Hannan¹, ¹Institute for Aging Research, Hebrew SeniorLife & Harvard Medical School, Boston, MA, ²Institute for Aging Research, Hebrew Senior Life, Boston, MA, ³Boston University School of Medicine, Boston, MA, ⁴Framingham Heart Study and Boston University, Framingham, MA, ⁵Department of Biostatistics, Boston University School of Public Health, Boston, MA, ⁶Institute for Aging Research, Hebrew SeniorLife, Dept. of Medicine Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Laboratory and animal studies suggest that lower sex hormone levels promote production and activity of pro-inflammatory cytokines that trigger bone resorption. This paradigm is…
Abstract Number: 1010 • 2012 ACR/ARHP Annual Meeting
Bone Loss Before Clinical Onset of Rheumatoid Arthritis o Subjects with Anti-Citrullinated Protein Antibodies
Stephanie Finzel¹, Veronika Lang², Arnd Kleyer¹, Juergen Rech³, Bernhard Manger¹, Elizabeth Araujo¹, Axel J. Hueber⁴, Ulrike Harre⁵ and Georg Schett¹, ¹Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Dept. of Medicine, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Germany, ³Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵Institute for Clinical Immunology, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) are a major risk factor for rapid disease progression in rheumatoid arthritis (RA). We have recently shown that ACPA directly…
Abstract Number: 2013 • 2012 ACR/ARHP Annual Meeting
Cross-Sectional and Longitudinal comparison of Bone Mass Status, Using pQCT, in a Large Cohort of Juvenile Idiopathic Arthritis and Juvenile Onset Systemic Lupus Erythematosus Patients
Fernanda Falcini¹, Stefano Stagi², Loredana Cavalli³, Giulia Carnesecchi⁴, Federico Bertini⁴, Laura Masi³, Marco Matucci-Cerinic⁵ and Maria Luisa Brandi³, ¹Department of Biomedicine, Division of Rheumatology AOUC, Excellence Centre for Research, Florence, Italy, ²Pediatric Unit,, Mugello's Hospital, Borgo San Lorenzo, Firenze, Italy, ³Department of Internal Medicine, Endocrinology Unit, University of Florence, Firenze, Italy, ⁴Department of Internal Medicine, Rheumatology Section, University of Florence, Florence, Italy, ⁵Medicine, Univ Florence, Firenze, Italy
Background/Purpose: A small number of prospective data have been published on the use of pQCT in large groups of pts with JIA and JSLE. Moreover,…
Abstract Number: 923 • 2012 ACR/ARHP Annual Meeting
Low Bone Mineral Density and Higher Parathyroid Hormone Levels As Independent Factors to All-Cause Mortality in Community-Dwelling Older Adults: the São Paulo Ageing & Health Study (SPAH)
Diogo S. Domiciano¹, Luana G. Machado², Jaqueline B. Lopes², Camille P. Figueiredo², Valéria Caparbo³, Liliam Takayama², Eloisa Bonfa⁴ and Rosa M.R. Pereira³, ¹Rheumatology, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil, ²Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Rheumatology, University of São Paulo, São Paulo, Brazil, ⁴Rheumatology Division, University of São Paulo, Sao Paulo, Brazil
Background/Purpose: Previous studies have shown a relationship between osteoporosis and increased risk of death. Moreover, secondary hyperparathyroidism has been linked to mortality amongst frail older…
Abstract Number: 1979 • 2012 ACR/ARHP Annual Meeting
Care Gap in the Treatment of Patients with High Risk for Fractures in a Single Canadian Academic Center
Arthur N. Lau¹, Michael Branch², Robert Bensen³, Jonathan D. Adachi⁴, Alexandra Papaioannou⁵, William Wong-Pack⁶ and William G. Bensen⁷, ¹Rheumatology and Clinical Epidemiology, Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ²CEO, Inovex, Oakville, ON, Canada, ³Rheumatology Health Team, Dr. Bensen's Rheumatology Clinic, Hamilton, ON, Canada, ⁴St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁵Geriatric Medicine, McMaster University, Hamilton, ON, Canada, ⁶Department Of Nuclear Medicine, Hamilton, ON, Canada, ⁷Department of Medicine, Division of Rheumatology, St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada
Background/Purpose: A number of clinical prediction tools are available to stratify patients into low, moderate and high risk for fractures in future. These tools are…
Abstract Number: 444 • 2012 ACR/ARHP Annual Meeting
Tocilizumab Improves Bone Mineral Density Compared with Abatacept in Patients with TNF Blockers-Resistant Active Rheumatoid Arthritis. an Open Label Randomized Controlled Trial
Kensuke Kume¹, Kanzo Amano¹, Susumu Yamada¹, Kazuhiko Hatta², Kuniki Amano³, Noriko Kuwaba⁴ and Hiroyuki Ohta⁵, ¹Rheumatology, Hiroshima Clinic, Hiroshima, Japan, ²Rheumatology, Hatta Clinic, Kure, Japan, ³Rheumatology, Sky Clinic, Hiroshima, Japan, ⁴Medical Research, Sanki Clinical Link, Hiroshima, Japan, ⁵Medical Research, hiroshima clinic, Hiroshima, Japan
Background/Purpose: To compare the effect of tocilizumab(TCZ) plus methotrexate (MTX), with the effect of abatacept(ABT) plus MTX on bone mineral density(BMD) in TNF blockers resistant…
Abstract Number: 1985 • 2012 ACR/ARHP Annual Meeting
The Effect of Calcium and Vitamin D On Bone Loss in an Epileptic Population
Philip Dussault¹, Samuel Davis Jr.² and Antonio A. Lazzari³, ¹Primary Care / Pharmacy, Boston VA HCS, Boston, MA, ²Osteoporosis, Boston VA HCS, Boston, MA, ³Prim Care/Rheumatology, Boston VA Medical Center, Boston, MA
Background/Purpose: Accelerated rate of bone loss leading to osteopenia and osteoporosis is a well recognized adverse effect of long term anticonvulsant use, particularly phenytoin,…
Abstract Number: 1987 • 2012 ACR/ARHP Annual Meeting
A Comparison of Unilateral and Bilateral Hip BMD
Steven C. Schaub¹, Edward S. Leib² and Diantha Howard³, ¹Medical School, U of Vermont College of Med, Burlington, VT, ²Medicine, U of Vermont College of Med, Burlington, VT, ³Statistics, Vermont Center for Clinical and Translational Science, Burlington, VT
Background/Purpose: The utility of bilateral hip dual energy x-ray absorptiometry scanning for identifying low bone mineral density has been a cause of debate. Intraperson differences…
Abstract Number: 1989 • 2012 ACR/ARHP Annual Meeting
Risk Factors for Vertebral Fractures in Patients with Rheumatoid Arthritis – the Tomorrow Study –
Tadashi Okano¹, Tatsuya Koike², Masahiro Tada¹, Kenji Mamoto³, Yuko Sugioka¹, Atsuko Kamiyama⁴ and Hiroaki Nakamura¹, ¹Orthopedic Surgery, Osaka City University Medical School, Osaka, Japan, ²Center for Senile Degenerative Disorders (CSDD), Osaka City University Medical School, Osaka, Japan, ³Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ⁴Rheumatosurgery, Osaka City University Medical School, Osaka, Japan
Background/Purpose: Rheumatoid arthritis (RA) is one of the causes for secondary osteoporosis. Osteoporosis as a multifactorial disease might be derived from comorbidity itself, poorer physical…
Abstract Number: 1992 • 2012 ACR/ARHP Annual Meeting
Anti-TNF Therapies Improve Bone Mineral Density At the Lumbar Spine of RA Patients by Decreasing Disease Activity and Suppressing Serum RANKL Levels
Allen P. Anandarajah¹, Jennifer Hossler², Kate Burns³, Kelly Callahan³, Yahui Grace Chiu³ and Jennifer H. Anolik⁴, ¹Dept of Rheumatology, Univ of Rochester Medical Ctr, Rochester, NY, ²Rheumatology, University of Rochester, Rochester, NY, ³Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁴Medicine- Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY
Background/Purpose: Generalized bone loss (osteoporosis or osteopenia) is more common in patients with rheumatoid arthritis (RA) than in the general population. Recent studies suggest that…
Abstract Number: 1996 • 2012 ACR/ARHP Annual Meeting
Are Changes in Bone Mineral Density Different Between Groups of Early Rheumatoid Arthritis Patients Treated According to a Tight Control Strategy with or without Prednisone, If Osteoporosis Prophylaxis Is Applied?
Marlies C. van der Goes¹, Johannes W.G. Jacobs¹, Maud S. Jurgens¹, Marije F. Bakker¹, Maaike J. van der Veen², Jacobine H. van der Werf³, Paco M.J. Welsing¹ and Johannes W.J. Bijlsma¹, ¹Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Rheumatology, St. Jansdal hospital, Harderwijk, Netherlands, ³Rheumatology, Diakonessenhuis, Utrecht, Netherlands
Background/Purpose: To describe effects on bone mineral density (BMD) of treatment according to EULAR guidelines with a methotrexate-based tight control strategy including 10 mg prednisone…
Abstract Number: 1997 • 2012 ACR/ARHP Annual Meeting
Safety and Efficacy of Denosumab Vs Ibandronate in Postmenopausal Women Sub-Optimally Treated with Daily or Weekly Bisphosphonates: A Randomized, Open-Label Study
Michael A. Bolognese¹, Edward Czerwinski², Henry G. Bone³, Sydney Bonnick⁴, Neil Binkley⁵, Alfred Moffett Jr.⁶, Suresh Siddhanti⁷, Irene Ferreira⁸, Prayashi Ghelani⁹, Rachel Wagman⁷, Jesse W. Hall⁷ and Chris Recknor¹⁰, ¹Bethesda Health Research Center, Bethesda, MD, ²Krakow Medical Center, Krakow, Poland, ³Michigan Bone and Mineral Clinic, Detroit, MI, ⁴Clinical Research Center of North Texas, Denton, TX, ⁵University of Wisconsin, Madison, WI, ⁶OB-GYN Associates of Mid Florida, PA, Leesburg, FL, ⁷Amgen Inc., Thousand Oaks, CA, ⁸Amgen Inc., Cambridge, United Kingdom, ⁹Ovatech Solutions, London, United Kingdom, ¹⁰United Osteoporosis Centers, Gainesville, GA
Background/Purpose: Denosumab, a fully human monoclonal antibody that specifically targets RANKL to inhibit osteoclast formation, function, and survival, reduces risk for vertebral, non-vertebral, and hip…
Abstract Number: 1998 • 2012 ACR/ARHP Annual Meeting
Relationship Between Changes in Bone Mineral Density and Incidence of Fracture with 6 Years of Denosumab Treatment
Michael A. Bolognese¹, Paul D. Miller², Jean-Yves Reginster³, Nathalie Franchimont⁴, Gerolamo Bianchi⁵, Roland Chapurlat⁶, Federico G. Hawkins⁷, David L. Kendler⁸, Beatriz Oliveri⁹, Jose R. Zanchetta¹⁰, Nadia Daizadeh⁴, Andrea Wang⁴, Rachel B. Wagman⁴ and Socrates Papapoulos¹¹, ¹Bethesda Health Research Center, Bethesda, MD, ²University of Colorado Health Sciences Center and Colorado Center for Bone Research, Lakewood, CO, ³Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium, ⁴Amgen Inc., Thousand Oaks, CA, ⁵LELICOMAR - Div Reumatologia, Azienda Sanitaria Genovese, Genoa, Italy, ⁶Hôpital Edouard Herriot, Lyon, France, ⁷Hospital Universitario, Madrid, Spain, ⁸University of British Columbia, Vancouver, BC, Canada, ⁹Laboratorio Enfermedades Metabólicas Oseas, Hospital de Clínicas, INIGEM UBA-CONICET, Buenos Aires, Argentina, ¹⁰Instituto de Investigaciones Metabólicas and University of Salvador, Buenos Aires, Argentina, ¹¹Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: During the first 3 years of denosumab treatment in FREEDOM, there were continued increases in bone mineral density (BMD) and a robust reduction in…
Abstract Number: 1970 • 2012 ACR/ARHP Annual Meeting
Utility of Spine Bone Mineral Density in Fracture Prediction within the Fracture Risk Assessment Tool (FRAX)
Tristan Blackburn¹, Diantha Howard² and Edward S. Leib³, ¹Rheumatology, Fletcher Allen Health Care, University of Vermont College of Medicine, Burlington, VT, ²Medicine, Vermont Center for Clinical and Translational Science, Burlington, VT, ³Medicine, Fletcher Allen Health Care, University of Vermont College of Medicine, Burlington, VT
Background/Purpose: Predicting which individuals are at risk to experience a fracture and modify that risk is important in preventative health. The WHO’s Fracture Risk Assesment…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].